Octapharma USA, a subsidiary of the largest privately owned plasma products company in the world, has selected Yankee Public Relations of Alexandria Township, N.J. as its public relations firm of record.
Hoboken, NJ (PRWEB) October 6, 2008 -- Octapharma USA, a subsidiary of the largest privately owned plasma products company in the world, has selected Yankee Public Relations of Alexandria Township, N.J. as its public relations firm of record.
"This year marks Octapharma's 25th anniversary and we are expecting tremendous growth in the very near future," said Octapharma USA President Flemming Nielsen. "Having seasoned, creative public relations talent behind us is vitally important to our company's business objectives. Fred Feiner and Yankee PR will be a tremendous asset as our company continues to grow."
Based in Lachen, Switzerland, Octapharma is responsible for the development, production and sale of high quality, virus safe plasma derivatives, including intravenous immunoglobulin (IVIG). In the U.S., Octapharma's IVIG product, octagam®, is used to treat disorders of the immune system and Octapharma's Albumin (Human) 5% is indicated for the restoration and maintenance of circulating blood volume.
"It is an outstanding opportunity to represent Octapharma USA at this important time in the company's history," said Yankee PR President Fred Feiner. "Even during a difficult business cycle for the pharmaceutical industry, Octapharma is thriving with sales continuing to outpace their competition. Demand for Octapharma products continues to build and significant U.S. growth is expected so it is a great time to be building the company's brand."
The Yankee PR team has over 20 years of experience in media relations, marketing communications and crisis management with particular expertise in the pharmaceutical, real estate and finance industries. Feiner's clients have included some of the largest development companies and investment funds on the East Coast, as well as leading-edge architecture, engineering and technology firms. For more information on the firm, please call 908-894-3930 or visit them at www.yankeepr.com.
Octapharma is the largest privately owned plasma fractionation company in the world. Its core business is the development, production and sale of high quality, virus safe plasma derivatives, including intravenous immunoglobulin (IVIG). From its foundation in 1983, the Swiss-based company has grown to employ over 2000 people in 27 countries, including the United States, where Octapharma USA is headquartered in Hoboken, N.J. Octapharma owns four modern, state-of-the-art production facilities in Vienna, Austria; Strasbourg, France; Stockholm, Sweden; and Mexico City, Mexico; and also operates a fifth fractionation facility in Springe, Germany. For more information, please visit www.octapharma.com or call 201-604-1130.
Read the full story at http://www.prweb.com/releases/octapharma/pharmaceutical/prweb1423854.htm
Copyright©2008 Vocus, Inc.
All rights reserved